famotidine (pepcid) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.   NCATS

Chemistry

  • SMILES: NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
  • InChIKey: XUFQPHANEAPEMJ-UHFFFAOYSA-N
  • Mol. Mass: 337.445
  • ALogP: -0.77
  • ChEMBL Molecule:
    famotidine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0506 - $7.6800

Australia

$0.0516 - $0.1031
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1-amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide | 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)propanimidamide | 3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-n(sup 2)-sulfamoylpropionamidine | agufam | amfamox | antodine | apogastine | bestidine | brolin | cepal | digervin | dispromil | famotidina | famotidine | famotidinum | fluxid | mk-2048 | mk-208 | n-sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide | pepcid | pepcid ac | pepcid rpd

Organizations (137)

Research & Development (97)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (45)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (52)

Approved Indications (5)


 

Arthritis, Rheumatoid

Duodenal Ulcer (approved 1986)

Heartburn (approved 1986)

Osteoarthritis

Stomach Ulcer (approved 1986)

Experimental Indications - Clinical Trial Phases 1-4 (51)


 

Acute Coronary Syndrome (Phase 4)

Analgesics, Opioid (Phase 4)

Anemia, Sickle Cell (Phase 2/Phase 3)

Anesthesia (Phase 4)

Arthritis, Juvenile (Phase 4)

Arthritis, Rheumatoid (Phase 3)

Aspirin (Phase 4)

Back Pain (Phase 3)

Biological Availability (Phase 1)

Brain Edema (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Chronic Pain (Phase 3)

Colorectal Neoplasms (Phase 1)

Coronary Disease (Phase 4)

COVID-19 (Phase 4)

Drug Interactions (Phase 1)

Dyskinesias (Phase 2)

Dyspepsia (Phase 4)

Eosinophilic Esophagitis (Phase 2)

Esophagitis (Phase 3)

Gastroesophageal Reflux ()

Healthy Volunteers (Phase 1)

Heartburn (Phase 4)

Heart Failure (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 2)

Hemorrhage (Phase 4)

HIV (Phase 4)

HIV Infections (Phase 4)

Immunoglobulin G4-Related Disease (Phase 2)

Intestinal Neoplasms (Phase 3)

Laryngomalacia (Phase 1/Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Lymphoma (Phase 3)

Melanoma (Phase 1)

Multiple Myeloma (Phase 2)

Myocardial Infarction (Phase 4)

Neoplasms (Phase 1)

Osteoarthritis (Phase 3)

Peptic Ulcer ()

Psoriasis (Phase 1)

Pulmonary Arterial Hypertension (Phase 2)

Respiratory Aspiration (Phase 4)

Schizophrenia (Phase 4)

Stomach Diseases (Phase 1)

Stomach Neoplasms (Phase 2)

Stomach Ulcer (Phase 4)

Stroke (Phase 2)

Thyroid Cancer, Papillary (Phase 1)

Ulcer (Phase 4)

Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial Organizations: 97

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue